Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis

Overview of attention for article published in Advances in Therapy, March 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,234 followers.

Economic burden of switching to a non TNFi vs a TNFi among patients with #rheumatoidarthritis https://t.co/YUDX5QtZ8u #cost